| Date Filed | Type | Description |
| 02/14/2023 |
SC 13G/A
| DODGE & COX reports a 5.3% stake in Sanofi |
| 02/10/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/07/2023 |
SC 13G/A
| BlackRock Inc. reports a 7.2% stake in SANOFI |
| 02/22/2022 |
SC 13G/A
| Amundi reports a 5.7% stake in Sanofi |
| 02/15/2022 |
SC 13G/A
| Amundi reports a 3.8% stake in Sanofi |
| 02/14/2022 |
SC 13G
| DODGE & COX reports a 5.6% stake in Sanofi |
| 02/08/2022 |
SC 13G
| Sanofi reports a 8.1% stake in Icosavax, Inc. |
| 02/03/2022 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 08/12/2021 |
SC 13D
| Form SC 13D - General statement of acquisition of beneficial ownership: |
| 03/31/2021 |
SC 13G
| Sanofi reports a 7% stake in LAVA Therapeutics N.V.1 |
| 02/16/2021 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
| 02/11/2021 |
SC 13G
| Sanofi reports a 4.6% stake in Revolution Medicines, Inc. |
| 02/04/2021 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
| 02/01/2021 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 06/17/2020 |
SC 13D/A
| Sanofi reports a 0.3% stake in Regeneron Pharmaceuticals, Inc. |
| 05/29/2020 |
SC 13D/A
| Sanofi reports a 21% stake in Regeneron Pharmaceuticals, Inc. |
| 02/10/2020 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/10/2020 |
SC 13G/A
| Sanofi reports a 0% stake in Exit Filing)* Regulus Therapeutics Inc. |
| 02/10/2020 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 12/09/2019 |
SC 13D/A
| Sanofi reports a 21.6% stake in Regeneron Pharmaceuticals, Inc. |
| 07/29/2019 |
SC 13G
| Sanofi reports a 2.4% stake in Fulcrum Therapeutics, Inc. |
| 05/03/2019 |
SC 13G/A
| Sanofi reports a 0% stake in Alnylam Pharmaceuticals, Inc. |
| 02/15/2019 |
SC 13G/A
| Sanofi reports a 0% stake in MyoKardia, Inc. |
| 02/12/2019 |
SC 13G/A
| Sanofi reports a 0% stake in SCYNEXIS, Inc. |
| 02/11/2019 |
SC 13G/A
| BlackRock Inc. reports a 6.2% stake in SANOFI SA |
| 02/11/2019 |
SC 13G/A
| Sanofi reports a 0% stake in Voyager Therapeutics, Inc. |
| 02/11/2019 |
SC 13G/A
| Sanofi reports a 10.4% stake in MyoKardia, Inc. |
| 02/11/2019 |
SC 13G
| Sanofi reports a 5.9% stake in Unum Therapeutics, Inc. |
| 06/19/2018 |
SC 13D/A
| Sanofi reports a 100% stake in Ablynx NV |
| 05/25/2018 |
SC 13D
| Sanofi reports a 95.6% stake in Ablynx NV |
| 02/13/2018 |
SC 13G/A
| Sanofi reports a 8.4% stake in Regulus Therapeutics Inc. |
| 02/13/2018 |
SC 13G/A
| Sanofi reports a 11.4% stake in Alnylam Pharmaceuticals, Inc. |
| 02/13/2018 |
SC 13G/A
| Sanofi reports a 11.2% stake in MyoKardia, Inc. |
| 02/13/2018 |
SC 13G/A
| Sanofi reports a 5.4% stake in SCYNEXIS, Inc. |
|